TCR2 THERAPEUTICS INC's ticker is TCRR and the CUSIP is 87808K106. A total of 81 filers reported holding TCR2 THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.39 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $61,032 | +129.0% | 40,688 | +52.5% | 0.00% | – |
| Q4 2022 | $26,652 | +48.1% | 26,684 | +161.3% | 0.00% | – |
| Q3 2022 | $18,000 | -10.0% | 10,213 | +48.8% | 0.00% | – |
| Q2 2022 | $20,000 | -37.5% | 6,865 | -40.8% | 0.00% | – |
| Q1 2022 | $32,000 | -69.2% | 11,602 | -48.0% | 0.00% | – |
| Q4 2021 | $104,000 | -45.0% | 22,291 | +0.3% | 0.00% | – |
| Q3 2021 | $189,000 | -82.5% | 22,217 | -66.2% | 0.00% | – |
| Q2 2021 | $1,077,000 | -20.2% | 65,645 | +7.4% | 0.00% | – |
| Q1 2021 | $1,350,000 | +23.1% | 61,121 | +72.4% | 0.00% | – |
| Q4 2020 | $1,097,000 | +60.9% | 35,453 | +5.7% | 0.00% | – |
| Q3 2020 | $682,000 | -12.9% | 33,552 | -34.3% | 0.00% | – |
| Q2 2020 | $783,000 | +380.4% | 51,031 | +141.3% | 0.00% | – |
| Q1 2020 | $163,000 | -41.4% | 21,152 | +8.9% | 0.00% | – |
| Q4 2019 | $278,000 | +118.9% | 19,426 | +129.5% | 0.00% | – |
| Q3 2019 | $127,000 | – | 8,466 | +60371.4% | 0.00% | – |
| Q2 2019 | $0 | – | 14 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| MPM BioImpact LLC | 6,741,964 | $208,528,000 | 18.01% |
| MPM ASSET MANAGEMENT LLC | 4,050,865 | $125,293,000 | 17.73% |
| Consonance Capital Management LP | 584,885 | $71,268,000 | 6.66% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 136,000 | $4,206,000 | 2.44% |
| Redmile Group, LLC | 2,832,888 | $87,621,000 | 1.06% |
| Altium Capital Management LP | 73,991 | $2,289,000 | 0.86% |
| PFM Health Sciences, LP | 775,794 | $23,995,000 | 0.84% |
| Soleus Capital Management, L.P. | 199,867 | $6,182,000 | 0.82% |
| MOODY ALDRICH PARTNERS LLC | 123,639 | $3,824,000 | 0.62% |
| Sofinnova Investments, Inc. | 333,707 | $10,322,000 | 0.61% |